(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.88%.
Alx Oncology Holdings's earnings in 2026 is -$80,890,000.On average, 8 Wall Street analysts forecast ALXO's earnings for 2026 to be -$86,506,089, with the lowest ALXO earnings forecast at -$97,568,249, and the highest ALXO earnings forecast at -$74,047,332. On average, 8 Wall Street analysts forecast ALXO's earnings for 2027 to be -$81,569,601, with the lowest ALXO earnings forecast at -$101,633,593, and the highest ALXO earnings forecast at -$62,432,064.
In 2028, ALXO is forecast to generate -$76,729,906 in earnings, with the lowest earnings forecast at -$108,409,166 and the highest earnings forecast at -$49,364,888.